Free Trial
→ SHOCKING! Prediction caught on camera (From Paradigm Press) (Ad)tc pixel Free WINT Stock Alerts

Windtree Therapeutics (WINT) Competitors

Windtree Therapeutics logo
$0.0002 -0.01 (-97.44%)
As of 11/13/2026 03:45 PM Eastern
Compare

WINT vs. LIPO, ZVSA, ALVOW, APLMW, and BIAFW

Should you buy Windtree Therapeutics stock or one of its competitors? Windtree Therapeutics's main competitors and comparable companies include Lipella Pharmaceuticals (LIPO), ZyVersa Therapeutics (ZVSA), Alvotech (ALVOW), Apollomics (APLMW), and bioAffinity Technologies (BIAFW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Windtree Therapeutics compare to Lipella Pharmaceuticals?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Windtree Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Windtree Therapeutics' return on equity of -207.34% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Windtree Therapeutics N/A -207.34%-50.19%

Windtree Therapeutics has lower revenue, but higher earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.01-$5.02M-$2.42N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Windtree Therapeutics Neutral

Lipella Pharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Lipella Pharmaceuticals and Windtree Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Windtree Therapeutics compare to ZyVersa Therapeutics?

Windtree Therapeutics (NASDAQ:WINT) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Windtree Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A

ZyVersa Therapeutics' return on equity of -109.54% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
ZyVersa Therapeutics N/A -109.54%-43.95%

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
ZyVersa Therapeutics Neutral

Summary

Windtree Therapeutics and ZyVersa Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Windtree Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Windtree Therapeutics (NASDAQ:WINT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Alvotech's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Windtree Therapeutics N/A -207.34%-50.19%

In the previous week, Alvotech had 7 more articles in the media than Windtree Therapeutics. MarketBeat recorded 7 mentions for Alvotech and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 beat Alvotech's score of -0.02 indicating that Windtree Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Neutral
Windtree Therapeutics Neutral

Alvotech has higher revenue and earnings than Windtree Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.95MN/AN/AN/AN/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

29.3% of Windtree Therapeutics shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Alvotech beats Windtree Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Windtree Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Windtree Therapeutics (NASDAQ:WINT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

29.3% of Windtree Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Windtree Therapeutics N/A -207.34%-50.19%

In the previous week, Apollomics had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for Windtree Therapeutics. Apollomics' average media sentiment score of 1.79 beat Windtree Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Very Positive
Windtree Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ApollomicsN/AN/AN/AN/AN/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

Summary

Apollomics beats Windtree Therapeutics on 4 of the 6 factors compared between the two stocks.

How does Windtree Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and Windtree Therapeutics (NASDAQ:WINT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

bioAffinity Technologies has higher revenue and earnings than Windtree Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

bioAffinity Technologies' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Windtree Therapeutics N/A -207.34%-50.19%

In the previous week, bioAffinity Technologies had 2 more articles in the media than Windtree Therapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for Windtree Therapeutics. bioAffinity Technologies' average media sentiment score of 1.25 beat Windtree Therapeutics' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company Overall Sentiment
bioAffinity Technologies Positive
Windtree Therapeutics Neutral

29.3% of Windtree Therapeutics shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

bioAffinity Technologies beats Windtree Therapeutics on 5 of the 7 factors compared between the two stocks.

Get Windtree Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WINT vs. The Competition

Export
MetricWindtree TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9K$4.12B$7.84B$12.19B
Dividend YieldN/A3.62%2.46%4.53%
P/E Ratio0.0025.7334.7128.44
Price / SalesN/A16.578.665.84
Price / CashN/A26.3721.9322.49
Price / Book0.004.004.353.76
Net Income-$1.79M-$22.78M$3.51B$390.55M
7 Day PerformanceN/A-2.85%-1.49%-0.33%
1 Month PerformanceN/A-3.75%-2.55%-4.82%
1 Year PerformanceN/A-1.56%0.92%-5.83%

Windtree Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WINT
Windtree Therapeutics
N/A$0.00
-97.4%		N/AN/A$9KN/AN/A14
LIPO
Lipella Pharmaceuticals
N/A$0.00
flat		N/AN/A$2K$536.36KN/A7
ZVSA
ZyVersa Therapeutics
N/A$0.00
-90.0%		N/AN/A$1KN/AN/A2
ALVOW
Alvotech
N/A$0.14
flat		N/AN/A$0.00$491.95MN/A1,460
APLMW
Apollomics
N/A$0.01
flat		N/AN/A$0.00$8.50MN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:WINT) was last updated on 11/15/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel